FDA Pulls Amputation Boxed Warning Off Canagliflozin Label

New safety information suggests the risk of amputation, while still increased with canagliflozin, is lower than previously described, particularly when appropriately monitored, the FDA said.
News Alerts

Source link

Related posts

Teaching Video NeuroImages: Cautious walking gait in siblings with hereditary hyperekplexia


Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson’s disease pathogenesis


How does aspirin influence the rupture risk of cerebral aneurysms?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy